ArticleWorld journal of pediatrics : WJP2008
Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants.
Article in World journal of pediatrics : WJP, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.Early human development · 2017Trial
- Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.European journal of pediatrics · 2017Trial
- Machine learning-based tool to assess risk of hemodynamically significant PDA in extremely premature infants.Pediatric research · 2026Article
- The association between patent ductus arteriosus and adverse outcomes in preterm infants.BMC pediatrics · 2026Article
- Impact of the Time to Initiation of Indomethacin or Ibuprofen on Patent Ductus Arteriosus Closure Rates.Paediatric drugs · 2026Article
- Factors Predicting Spontaneous Closure of Patent Ductus Arteriosus in Very Low Birth Weight Neonates.Cureus · 2024Article
- Association between endotypes of prematurity and pharmacological closure of patent ductus arteriosus: A systematic review and meta-analysis.Frontiers in pediatrics · 2023Article
- Sex Differences in Patent Ductus Arteriosus Incidence and Response to Pharmacological Treatment in Preterm Infants: A Systematic Review, Meta-Analysis and Meta-Regression.Journal of personalized medicine · 2022Review
- Predictors of successful patent ductus arteriosus closure with acetaminophen in preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2021Article
- Efficacy and Safety of Oral Acetaminophen for Premature Infants With Patent Ductus Arteriosus: A Meta-Analysis.Frontiers in pharmacology · 2021Review
- Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.Pediatric cardiology · 2018Review
- Oral Paracetamol for Patent Ductus Arteriosus Rescue Closure.Pediatric cardiology · 2018Article
- Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants.Archives of disease in childhood. Fetal and neonatal edition · 2016Article
- Intravenous paracetamol for PDA closure in the preterm: a single-center experience.European journal of pediatrics · 2016Observational
- B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants.Acta paediatrica (Oslo, Norway : 1992) · 2013Article
- Patent ductus arteriosus in preterm infants: do we have the right answers?BioMed research international · 2013Review
- Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.BMC pediatrics · 2012Article
- Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?Clinics (Sao Paulo, Brazil) · 2011Review
- Potential Unintended Consequences of a Conservative Management Strategy for Patent Ductus Arteriosus.Congenital heart diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of patent ductus arteriosus (PDA) is high in extremely low birth weight (ELBW) infants. Indomethacin has been widely used in the prophylaxis and treatment of hemodynamically significant PDA. This retrospective study was undertaken to identify factors such as birth weight, gestational age, gender, fetal growth retardation, ductal size, timing of the first dose of indomethacin and side effects of indomethacin, which may affect the successful closure of the PDA with indomethacin in ELBW infants.
methodsA cohort of 139 ELBW infants who had received indomethacin treatment for PDA during a consecutive period of more than three years (September 2000 to December 2003) was retrospectively analyzed. Administration
resultsof indomethacin was associated with closure of PDA in 108 (77.7%) of 139 ELBW infants, and only 19.4% of infants required surgical ligation of the ductus eventually. There was no significant relationship between closure of PDA with gestational age, gender, fetal growth retardation, and ductal size. A higher birth weight and early use of indomethacin after birth could significantly increase the closure rate of PDA (P<0.05). Side effects of indomethacin such as transient oliguria and hyponatremia during indomethacin therapy did not affect PDA closure.
conclusionsIndomethacin is effective for the treatment of PDA in ELBW infants. A higher rate of ductal closure is related to the increase of birth weight. PDA closure with indomethacin is age-related, and early administration of indomethacin could increase PDA closure and reduce the incidence of hyponatremia. There is no significant difference in major morbidities such as bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and retinopathy of prematurity (ROP) after early treatment. Early screening for hemodynamically significant PDA in ELBW infants and early treatment with indomethacin are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.